INTESTINAL PERFUSION AND PERMEABILITY IN SEPSIS

脓毒症的肠道灌注和渗透性

基本信息

  • 批准号:
    2392016
  • 负责人:
  • 金额:
    $ 29.05万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1987
  • 资助国家:
    美国
  • 起止时间:
    1987-04-01 至 2000-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION: (Adapted from the applicant's abstract) This competing renewal application is based on the hypothesis that gut epithelial barrier function is deranged by cellular acidosis. In the currently funded research, the investigator has shown that ileal mucosal acidosis in pigs increases mucosal permeability in vivo, and that exposure of mucosal cell (CaCo-2BBe) monolayers to acid also induce an increase in epithelial permeability in vitro. The investigator's studies have also shown that acidosis promotes lipid peroxidation, increases intracellular Fe2+, and partly depletes cellular ATP in the CaCo-2BBe enterocytes. These studies have demonstrated also that inhibition of calpain and phospholipases ameliorated acid induced mucosal hyperpermeability. These studies collectively support the concept that intracellular calcium related derangements may be important in the pathogenesis of acid induced mucosal barrier dysfunction. The present proposal will extend the studies of CaCo-2BBe cells and monocytes by: 1) measuring intracellular [H+], 2) assessing the effect of acidosis and ATP depletion on epithelial permeability to water soluble macromolecule as well as to particulate matter such as LPS and E.coli bacteria. In addition the proposal will focus on cytoskeletal integrity and its relationship to acidosis induced mucosal cell permeability dysfunction in CaCo-2BBe monolayers. Studies will evaluate also the effect of acidosis or moderate ATP depletion in the enterocytes on [Ca2+]i, and the effects of A23187, BAPTA, and various modifiers of phospholipases calpains and PKC on the acid and/or low ATP level induced mucosal permeability dysfunction. all of the aforementioned studies are to be carrier in the CaCo-2BBe cell line in vitro. Finally, experiments will ascertain the various determinants of ileal mucosal permeability dysfunction in the in vivo studies in a rat model of hemorrhagic injury. These studies will employ in vivo methodology to determine both translocation of LPS and permeability of macromolecules across the ileal epithelium.
描述:(改编自申请人的摘要)本次竞赛

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Mitchell P. Fink其他文献

Effects of nonsteroidal anti-inflammatory drugs on renal function in septic dogs.
非甾体抗炎药对脓毒症犬肾功能的影响。
  • DOI:
    10.1016/0022-4804(84)90135-5
  • 发表时间:
    1984
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Mitchell P. Fink;Thomas J. MacVittie;Larry C. Casey
  • 通讯作者:
    Larry C. Casey
Postoperative complications in patients with disabling psychiatric illnesses or intellectual handicaps. A case-controlled, retrospective analysis.
患有致残性精神疾病或智力障碍的患者的术后并发症。
  • DOI:
    10.1001/archsurg.1990.01410230030005
  • 发表时间:
    1990
  • 期刊:
  • 影响因子:
    0
  • 作者:
    B. Cutler;Mitchell P. Fink
  • 通讯作者:
    Mitchell P. Fink
Biology of heterotrimeric G-protein signaling.
异源三聚体 G 蛋白信号传导生物学。
  • DOI:
  • 发表时间:
    2000
  • 期刊:
  • 影响因子:
    8.8
  • 作者:
    R. Forse;John M. Luce;Michael B. Yaffe;Mitchell P. Fink
  • 通讯作者:
    Mitchell P. Fink
Hemorrhagic Ascites: An Unusual Presentation of Primary Splenic Lymphoma
  • DOI:
    10.1016/s0016-5085(82)80346-6
  • 发表时间:
    1982-08-01
  • 期刊:
  • 影响因子:
  • 作者:
    Joseph F. Hacker;Joel E. Richter;Robert S. Pyatt;Mitchell P. Fink
  • 通讯作者:
    Mitchell P. Fink
CRISIS IN CRITICAL CARE The Demand for Critical Care Services is Increasing Critical care
重症监护危机 对重症监护服务的需求正在增加 重症监护
  • DOI:
  • 发表时间:
    2005
  • 期刊:
  • 影响因子:
    0
  • 作者:
    David T. Huang;T. Osborn;K. Gunnerson;Scott R. Gunn;Stephen Trzeciak;Edward Kimball;Mitchell P. Fink;De Angus;R. Dellinger;Emanuel P. Rivers
  • 通讯作者:
    Emanuel P. Rivers

Mitchell P. Fink的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Mitchell P. Fink', 18)}}的其他基金

MOLECULAR BASIS FOR EPITHELIAL BARRIER DYSFUNCTION/PROJECT 2
上皮屏障功能障碍的分子基础/项目 2
  • 批准号:
    6829217
  • 财政年份:
    2004
  • 资助金额:
    $ 29.05万
  • 项目类别:
Ethyl Pyruvate: A Novel Treatment for Sepsis
丙酮酸乙酯:脓毒症的新型治疗方法
  • 批准号:
    6765286
  • 财政年份:
    2003
  • 资助金额:
    $ 29.05万
  • 项目类别:
Ethyl Pyruvate: A Novel Treatment for Sepsis
丙酮酸乙酯:脓毒症的新型治疗方法
  • 批准号:
    6911508
  • 财政年份:
    2003
  • 资助金额:
    $ 29.05万
  • 项目类别:
Ethyl Pyruvate: A Novel Treatment for Sepsis
丙酮酸乙酯:脓毒症的新型治疗方法
  • 批准号:
    6669337
  • 财政年份:
    2003
  • 资助金额:
    $ 29.05万
  • 项目类别:
COMPLEMENT-DEPENDENT PROSTAGLANDIN SYNTHESIS IN SEPSIS
脓毒症中补体依赖性前列腺素合成
  • 批准号:
    3466035
  • 财政年份:
    1987
  • 资助金额:
    $ 29.05万
  • 项目类别:
INTESTINAL PERFUSION AND PERMEABILITY IN SEPSIS
脓毒症的肠道灌注和渗透性
  • 批准号:
    2684840
  • 财政年份:
    1987
  • 资助金额:
    $ 29.05万
  • 项目类别:
INTESTINAL PERFUSION AND PERMEABILITY IN SEPSIS
脓毒症的肠道灌注和渗透性
  • 批准号:
    2178852
  • 财政年份:
    1987
  • 资助金额:
    $ 29.05万
  • 项目类别:
COMPLEMENT-DEPENDENT PROSTAGLANDIN SYNTHESIS IN SEPSIS
脓毒症中补体依赖性前列腺素合成
  • 批准号:
    3466038
  • 财政年份:
    1987
  • 资助金额:
    $ 29.05万
  • 项目类别:
COMPLEMENT-DEPENDENT PROSTAGLANDIN SYNTHESIS IN SEPSIS
脓毒症中补体依赖性前列腺素合成
  • 批准号:
    3466034
  • 财政年份:
    1987
  • 资助金额:
    $ 29.05万
  • 项目类别:
INTESTINAL PERFUSION AND PERMEABILITY IN SEPSIS
脓毒症的肠道灌注和渗透性
  • 批准号:
    2178851
  • 财政年份:
    1987
  • 资助金额:
    $ 29.05万
  • 项目类别:

相似国自然基金

Apocynin和allopurinol对运动上调自发性高血压大鼠肾脏一氧化氮合成酶表达的影响
  • 批准号:
    81301667
  • 批准年份:
    2013
  • 资助金额:
    23.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Allopurinol Improves Diastolic Function in African Americans with Resistant Hypertension
别嘌呤醇可改善患有难治性高血压的非裔美国人的舒张功能
  • 批准号:
    10701217
  • 财政年份:
    2023
  • 资助金额:
    $ 29.05万
  • 项目类别:
Association Between Allopurinol and Cardiovascular Events, Mortality and End-Stage Renal Disease in Diabetes
别嘌呤醇与糖尿病心血管事件、死亡率和终末期肾病之间的关联
  • 批准号:
    377029
  • 财政年份:
    2017
  • 资助金额:
    $ 29.05万
  • 项目类别:
    Fellowship Programs
CKD-FIX: a randomised, controlled trial of allopurinol in the slowing of kidney disease progression
CKD-FIX:别嘌呤醇减缓肾脏疾病进展的随机对照试验
  • 批准号:
    nhmrc : GNT1043203
  • 财政年份:
    2013
  • 资助金额:
    $ 29.05万
  • 项目类别:
    Project Grants
PERL: A multi-center clinical trial of allopurinol to prevent GFR loss in T1D
PERL:别嘌呤醇预防 T1D 患者 GFR 损失的多中心临床试验
  • 批准号:
    9738022
  • 财政年份:
    2013
  • 资助金额:
    $ 29.05万
  • 项目类别:
PERL: A multicenter clinical trial of allopurinol to prevent GFR loss in T1D
PERL:别嘌呤醇预防 T1D 患者 GFR 损失的多中心临床试验
  • 批准号:
    8644403
  • 财政年份:
    2013
  • 资助金额:
    $ 29.05万
  • 项目类别:
A multicenter clinical trial of allopurinol to prevent GFR loss in T1D
别嘌呤醇预防 1 型糖尿病 GFR 损失的多中心临床试验
  • 批准号:
    8445008
  • 财政年份:
    2012
  • 资助金额:
    $ 29.05万
  • 项目类别:
Design of a Multicenter Clinical Trial of Allopurinol to Prevent GFR Loss in T1D
别嘌呤醇预防 1 型糖尿病 GFR 损失的多中心临床试验设计
  • 批准号:
    8250159
  • 财政年份:
    2011
  • 资助金额:
    $ 29.05万
  • 项目类别:
Analysis of the mechanisms of allopurinol-induced severe cutaneous adverse reactions
别嘌呤醇致严重皮肤不良反应的机制分析
  • 批准号:
    23790611
  • 财政年份:
    2011
  • 资助金额:
    $ 29.05万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
ALLOPURINOL AND CARDIAC FUNCTION IN IDIOPATHIC DILATED CARDIOMYOPATHY
特发性扩张型心肌病中别嘌呤醇与心脏功能
  • 批准号:
    7199117
  • 财政年份:
    2004
  • 资助金额:
    $ 29.05万
  • 项目类别:
ALLOPURINOL AND THE PREVENTION OF DEATH, TISSUE INJURY, AND SEIZURES IN CHD
别嘌呤醇与预防冠心病死亡、组织损伤和癫痫发作
  • 批准号:
    6116864
  • 财政年份:
    1998
  • 资助金额:
    $ 29.05万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了